Shares of Oncobiologics Inc (NASDAQ:ONS) have earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Brokerages have set a one year consensus target price of $11.00 for the company, according to Zacks. Zacks has also given Oncobiologics an industry rank of 98 out of 265 based on the ratings given to its competitors.

Oncobiologics (ONS) traded up $0.13 during mid-day trading on Wednesday, reaching $1.42. The company had a trading volume of 1,167,930 shares, compared to its average volume of 108,826. Oncobiologics has a fifty-two week low of $0.78 and a fifty-two week high of $3.95. The company has a debt-to-equity ratio of -0.01, a quick ratio of 0.03 and a current ratio of 0.03.

A hedge fund recently raised its stake in Oncobiologics stock. Sabby Management LLC raised its stake in Oncobiologics Inc (NASDAQ:ONS) by 5.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,365,763 shares of the company’s stock after purchasing an additional 127,293 shares during the quarter. Sabby Management LLC owned 9.59% of Oncobiologics worth $2,371,000 as of its most recent filing with the Securities & Exchange Commission. 18.52% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/06/oncobiologics-inc-ons-given-11-00-average-target-price-by-brokerages.html.

About Oncobiologics

Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.

Get a free copy of the Zacks research report on Oncobiologics (ONS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oncobiologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.